Voyager Pharmaceutical, which has a potential drug treatment for Alzheimer’s disease in clinical trial, has reached into the ranks of a leading Alzheimer’s organization to expand its management ranks.
The company said Monday that it hard hired Sheldon Goldberg, president and chief executive officer of the Alzheimer’s Association, to be its senior vice president of corporate development. The position is a new one at Voyager.
Voyager recently completed a Phase II trial that included only women for its proposed Alzheimer’s drug. A study for men is also underway. The company is privately held and has raised more than $40 million from individuals. It closed on $16 million in financing in February.
Voyager said Goldberg would give up his positions at the Alzheimer’s group.
“Joining Voyager is the natural next step in my personal quest to provide patients and caregivers with an effective medical treatment for Alzheimer’s disease,” Goldberg said in a statement. “I take great pride in having supported many ambitious research programs during my time at the Alzheimer’s Association, and believe that my efforts at Voyager may finally give rise to an effective therapy that we all have been looking for.”
Goldberg has more than 30 years of experience as a manager, including previous positions as president and CEO at both the Jewish Home and Hospital and American Association of Homes and Services for the Aging.
Goldberg is also chairman of the board of business ventures at AARP.
“(Goldberg’s) unequaled expertise working across the entire breadth of healthcare on behalf of Alzheimer’s disease patients and their families brings the company rapidly closer in achieving its mission to deliver cures for the diseases of aging,” said Patrick Smith, CEO of Voyager.